JoelPThompsonMDMPH

PubMed

• Decreased portal vein attenuation and liver enhancement with reduced intravenous contrast dosage during the national iodinated contrast shortage of 2022.
  Robert Ranger, Don Truong, Joel Thompson> ;Journal of Clinical Imaging Science. 2024 Jan 1
• Incidental detection of benign metastasizing leiomyoma in asymptomatic female.
  Hannah E Zazulak, Meghan Single, Timothy O'Herron, Joel P Thompson> ;Journal of Clinical Imaging Science. 2023 Jan 1
• 3 citations
  Identification of Left Ventricle Failure on Pulmonary Artery CTA: Diagnostic Significance of Decreased Aortic & Left Ventricle Enhancement.
  Abhishek Chaturvedi, Joel P. Thompson, Katherine Kaproth-Joslin, Susan K. Hobbs, Karl Q. Schwarz, Vijay Krishnamoorthy, Apeksha Chaturvedi, Timothy M. Baran> ;Emergency Radiology. 2017 Mar 29
• Testicular Microlithiasis in the Setting of Primary Extragonadal Germ Cell Tumor: A Case Series
  Joel P. Thompson, Jerome Jean-Gilles, Vikram S. Dogra> ;Ultrasound Quarterly. 2017 Mar 1
• 2 citations
  Identify Before Orchiectomy: Segmental Testicular Infarct.
  Joel P. Thompson, Shweta Bhatt, Deborah J. Rubens> ;Ultrasound Quarterly. 2015 Sep 1
• 17 citations
  Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.
  Joel P. Thompson, Amir Abdolahi, Katia Noyes> ;Pharmacoeconomics. 2013 May 3
• 208 citations
  Funding of US biomedical research, 2003-2008
  E. Ray Dorsey, Jason de Roulet, Joel P. Thompson, Jason I. Reminick, Ashley Thai, Zachary White-Stellato, Christopher A. Beck, Benjamin P. George, Hamilton Moses> ;JAMA. 2010 Jan 13
• 33 citations
  Financing of U.S. Biomedical Research and New Drug Approvals across Therapeutic Areas
  E. Ray Dorsey, Joel P. Thompson, Melisa Carrasco, Jason de Roulet, Philip Vitticore, Sean Nicholson, S. Claiborne Johnston, Robert G. Holloway, Hamilton Moses> ;Plos One. 2009 Sep 11
• 7 citations
  Selegiline shortage Causes and costs of a generic drug shortage
  E. R. Dorsey, Joel P. Thompson, E. J. Dayoub, Benjamin P. George, L. A. Saubermann, Robert G. Holloway> ;Neurology. 2009 Jul 21
• Quantitative risk-benefit analysis of natalizumab.
  Israel Steiner> ;Neurology. 2009 May 19
• 4 citations
  Funding of Parkinson research from industry and US Federal and foundation sources
  E. Ray Dorsey, Joel P. Thompson, Mark Frasier, Todd Sherer, Brian K. Fiske, Sean Nicholson, S. Claiborne Johnston, Robert G. Holloway, Hamilton Moses> ;Movement Disorders. 2009 Apr 15
• 17 citations
  Public Reporting of Quality Data for Stroke. Is It Measuring Quality
  Adam G. Kelly, Joel P. Thompson, Deborah Tuttle, Curtis G. Benesch, Robert G. Holloway> ;Stroke. 2008 Dec 1
• 4 citations
  Quantitative risk-benefit analysis of natalizumab.
  J P Thompson, K Noyes, E R Dorsey, S R Schwid, R G Holloway> ;Neurology. 2008 Jul 29
• 93 citations
  Reply from the authors [4]
  Petros C. Karakousis, Shelley S. Magill, Amita Gupta> ;Neurology. 2007 Jul 1
• 17 citations
  Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
  E. R. Dorsey, Joel P. Thompson, Katia Noyes, Andrew W. Dick, Robert G. Holloway, Steven R. Schwid> ;Neurology. 2007 May 1
• 1047 citations
  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.
  E R Dorsey, R Constantinescu, J P Thompson, K M Biglan, R G Holloway, K Kieburtz, F J Marshall, B M Ravina, G Schifitto, A Siderowf, C M Tanner> ;Neurology. 2007 Jan 30
• 30 citations
  Financial anatomy of neuroscience research.
  E. Ray Dorsey, Philip Vitticore, Jason de Roulet, Joel P. Thompson, Melisa Carrasco, S. Claiborne Johnston, Robert G. Holloway, Hamilton Moses> ;Annals of Neurology. 2006 Dec 1
• Join now to see all